These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 16445417)

  • 1. Etanercept for psoriasis in the pediatric population: experience in nine patients.
    Hawrot AC; Metry DW; Theos AJ; Levy ML
    Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept for the treatment of psoriasis.
    Bissonnette R
    Skin Therapy Lett; 2006 Feb; 11(1):1-4. PubMed ID: 16485060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
    Yamauchi PS; Gindi V; Lowe NJ
    Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience with etanercept in the treatment of psoriasis].
    Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
    Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.
    Langley RG; Paller AS; Hebert AA; Creamer K; Weng HH; Jahreis A; Globe D; Patel V; Orlow SJ
    J Am Acad Dermatol; 2011 Jan; 64(1):64-70. PubMed ID: 20619489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
    Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
    J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
    Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of biologic agents in pediatric psoriasis.
    Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
    J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of severe nail psoriasis with etanercept.
    Coelho JD; Diamantino F; Lestre S; Ferreira AM
    Indian J Dermatol Venereol Leprol; 2011; 77(1):72-4. PubMed ID: 21220889
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
    Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
    Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adolescent plaque psoriasis: our experience using etanercept.
    Ruiz-Villaverde R; Sánchez-Cano D; Abalos-Medina G
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):976-7. PubMed ID: 19207668
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two years of experience with etanercept in recalcitrant psoriasis.
    Ahmad K; Rogers S
    Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of erythrodermic psoriasis with etanercept.
    Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
    Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
    Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
    de Vlam K; Lories RJ
    Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial experience with routine administration of etanercept in psoriasis.
    de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
    Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.